Heron Therapeutics Stock News

AbbVie, Adverum Biotechnologies, and Heron Therapeutics could all be gearing up for a strong May. Here's why.

Heron Therapeutics, Inc. (NASDAQ:HRTX) just released its latest quarterly results and things are looking bullish. The...

Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Ashland Global Holdings, Lyft and Solaredge Technologies, on Thursday. HIG

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 9.52% and 25.36%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most importan

If you own shares in Heron Therapeutics, Inc. (NASDAQ:HRTX) then it's worth thinking about how it contributes to the...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Baxter International (BAX), Biogen (BIIB) and Emergent Biosolutions

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Baxter International (BAX – Research

Heron Therapeutics (NASDAQ:HRTX) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Thursday, Zacks.com reports. According to Zacks, “Her

In 2013, Barry Quart was appointed CEO of Heron Therapeutics, Inc. (NASDAQ:HRTX). First, this article will compare CEO...

Brokerages predict that Heron Therapeutics Inc (NASDAQ:HRTX) will post sales of $20.89 million for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for Heron Therape

Analysts expect Heron Therapeutics Inc (NASDAQ:HRTX) to report earnings of ($0.62) per share for the current quarter, according to Zacks. Four analysts have issued estimates for Heron Therapeutics’